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COVID-19 (C-19) Vaccination – Intramuscular (IM) injection technique  
Word count: 1962 excluding tables and figures 
Key words: COVID-19, Intramuscular injection, vaccination, safety, technique 
Key points:  
• Nurses are the driving force behind the C-19 mass vaccination programme 
• Correct IM injection technique will ensure vaccinee safety and generate the most effective 
immune response  
• Nurses should ensure they utilise the contemporary evidence base to avoid ritualistic 
practices in relation to IM vaccine administration 
• A robust understanding of C-19 vaccines will ensure practitioners are able to provide informed 
information and support to vaccinees 
Reflective questions  
• What factors should be considered prior to administering the C-19 vaccination to the 
individual? 
• Regarding IM injection technique procedure, what areas of your practice have changed or 
been enhanced in relation to C-19 vaccination procedure?  
• What are the differences and similarities between the available vaccines?  
• How would you describe the technique for C-19 vaccination to a potential vaccinee or a 
colleague you are supervising?  
Introduction / overview 
COVID-19 (C-19) vaccinations are a key strategy to facilitate emergence from the current pandemic 
and the most effective way to protect the population, saving thousands of lives. It is hoped that the 
programme will expand, with a view to offering vaccination to all adults by the autumn of 2021 
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(Department of Health and Social Care, 2021). The current C-19 vaccination programme is the largest 
seen in NHS history (NHS England, 2020), with an estimated 80,000 strong workforce recruited, a 
significant number of those from fields of nursing. As such, effective and evidence-based 
intramuscular (IM) injection technique is an essential training requirement for all of those involved in 
vaccine administration within the programme.  
To date, 3 vaccines have been approved for use within the UK, a comparison of the vaccines is found 
in table 1. It should be noted that at the time of writing, that whilst approved, the Moderna vaccine is 
not currently available within the UK and as such, PHE will update the programme guidance for 
healthcare workers once available (PHE, 2021a).  
Practitioners should be aware of their individual role within the vaccination programme and should 
complete all required training alongside the practical assessment of competency. Not all vaccinators 
will draw up and those drawing up may not give the vaccine, depending on local arrangements. The 
COVID-19 vaccinator competency assessment tool (PHE, 2020b) details the required competencies 
based on the practitioner’s role within the vaccination programme and should be completed prior to 
commencing vaccination procedures.  
IM injection ensures deposition of medication beyond the sub cutaneous tissue into the deep muscle; 
due to the vascular nature of muscle tissue, this enables rapid absorption (Grafton et al, 2020). IM 
administration of C-19 vaccines generates effective immune response as appropriate cells are present 
in the muscle tissue, to initiate the response (PHE, 2021a). It is vital to avoid ritualistic practices when 
carrying out IM vaccination; nurses should utilise appropriate evidence to inform their practice 
(Greenway , 2014). 
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Vaccine composition (of 
note) 
 
Storage and shelf life Reconstitution Doses per 
vial 













No animal products 
+2°C and +8°C. Use within 6 
hours of vial puncture and 
then discard. Vial can be 
stored between at +2°C to 




8 doses of 
0.5ml or 10 
doses of 
0.5ml 
0.5ml via IM 
injection via 1ml 
dose sparing 
syringe with 23g or 
25g needle 
2 doses with a 
minimal interval 












glycol (PEG) – allergy to 




No animal products 
-80°C to -60 °C (6 months). 
Thawed at 2°C to 8 °C (5 days) 
Additional 2 hours up to 25°C 









6 doses of 
0.3ml 
0.3ml via IM 





2 doses with a 
minimal interval 










glycol (PEG) – allergy to 




No animal products 
-25°C to -15°C (7-month shelf 
life at this temperature. Once 
thawed, store at 2°C to 8°C 
for up to 30 days. Unopened 





10 doses of 
0.5ml 
0.5ml via IM 
injection via a 1ml 
syringe with a 23g / 
25g needle 
(supplied) 
2 doses with a 
minimal interval 
of 28 days 
* It is recommended that the second dose of vaccines should be routinely scheduled between four and 12 weeks after the first dose. This will allow more 
people to benefit from the protection provided from the first dose during the roll out phase and will have a greater impact in reducing mortality, severe 
disease, and hospitalisation. Evidence from Phase 3 trials indicate high levels of protection against serious disease and death from around 2 weeks after the 
first dose. Longer term protection will then be provided by the second dose.
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Informed consent  
NMC (2018) outlines the need to always act in the best interests of people, ensuring informed consent 
is obtained and documented prior to carrying out any action; this includes the administration of 
vaccines. There is no legal requirement for consent to vaccination to be in writing, consent must be 
given freely, the premise of ‘informed’ being justified by the individual being aware of the process, 
benefits, risks and be able to communicate that decision (PHE, 2013). Vaccinators must ensure they 
have obtained informed consent from the individual or person legally able to act on the persons 
behalf. Where there is a lack of capacity, a decision to vaccinate can be made in the persons best 
interests (PHE, 2021a). It is good practice to reconfirm consent prior to each vaccination.   
Contraindications and considerations for dosing 
Contraindications to vaccination should be assessed prior to administration.  
• Previous systemic allergic reaction to a previous dose of the same vaccine  
• Previous systemic allergic reaction to any excipients of the vaccine, including PEG (Pfizer and 
Moderna vaccines only) 
• Individuals with localised urticarial (itchy) skin reactions (without systemic symptoms) to the 
first dose, should receive the second dose with prolonged observation (30 minutes) in a 
setting with full resuscitation facilities.  
• Individuals with previous history of anaphylaxis not related to components of C-19 vaccines 
can be vaccinated 
• Localised injection site reaction to first dose is not a contraindication to further dosing  
• Individuals with bleeding disorders can be immunised if this is deemed reasonably safe by a 
doctor familiar with the persons bleeding risk 
• There is insufficient evidence to routinely recommend C-19 vaccination in pregnancy, but 
pregnant women should receive vaccination if benefits outweigh the risks; for example, those 
with co-morbidities.  Within the UK, the UK vaccine in pregnancy surveillance programme 
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seeks to compile additional information about women who are immunised with specified 
vaccines whilst pregnant to monitor the outcome of such exposures. This data being utilised 
to gain further information to guide practice and provide information. All COVID-19 vaccines 
given from the first day of last menstrual period to any time in pregnancy should be reported 
to the UK vaccine in pregnancy surveillance programme (PHE, 2021c) 
• Minor illnesses without fever or systemic upset are not valid reasons to postpone 
immunisation, unless acutely unwell. Vaccination should be postponed avoiding wrongly 
attributing symptoms to adverse effects of vaccination 
• C-19 vaccination should not be given within 7 days of another vaccine – again, to avoid 
wrongly attributing side effects to either vaccine 
• There is no evidence of safety concerns for vaccinating individuals with previous history of C-
19 infection. Vaccination should be deferred for 4 weeks after positive tests / symptoms.  
(adapted from PHE, 2021a, PHE, 2021b, JCVI, 2020; RCOG, 2020) 
Figure 1 provides a flowchart for managing patients who have allergic reactions to the first dose of 
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Infection prevention and control (IPC) 
All those attending for vaccination and those delivering vaccination should wear appropriate personal 
protective equipment (PPE) as described in the infection prevention and control (IPC) advice current 
at the time of administering the vaccine. Gloves are not necessary for vaccine clinics unless there is a 
risk of contact with blood or bodily fluids (PHE, 2020b) but vaccinators should follow PHE guidance for 
IPC regarding appropriate PPE in their area (Brown and Nickalls, 2021). Hand hygiene is critical to 
prevent the spread of infection and hands should be cleaned with alcohol-based gel or soap and water 
before vaccine preparation, and between patients. Those preparing and administering the vaccine 
should maintain good hand hygiene throughout and should take care not to touch the vial bung with 
their fingers (PHE, 2021a). 
Drawing up 
Manufacturers of all 3 approved UK vaccines recommend the use of 23g (blue) or 25g (orange) 
needles, 25mm in length. Some will come with the required needles and syringes (see table 1). Longer 
length needles (38mm) are recommended for morbidly obese individuals to ensure the vaccine is 
injected into muscle; Greenway (2014) cites needle length (rather than width) is critical to the 
effectiveness of IM injection.  
If dose sparing needles and syringes are used, it should be possible to obtain the full 6, 8 or 10 doses 
from the vial (see table 1 – ‘doses per vial’). Care should be taken to ensure the full dose is withdrawn 
from the vial, where a full dose cannot be extracted, the remaining contents should be discarded.  
The vial should be wiped with an alcohol swab and allowed to fully air dry. The required dose should 
be removed from the vial, taking care to ensure the correct dose is drawn up. Air bubbles should be 
removed before removing the needle from the vial to avoid losing any vaccine dose. The needle must 
not be changed between drawing up and administering the vaccine unless it is contaminated or 
damaged. (PHE, 2021a) 
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Injection site 
The area for injection should be clearly visible and accessible. Garments with long or tight sleeves may 
need to be removed. COVID-19 vaccines should be administered by intramuscular (IM) injection, 
preferably into the deltoid muscle of the upper arm. Individuals who have minimal muscle mass in the 
deltoid area of the upper arm, or a particular reason to avoid immunisation in the deltoid muscle, can 
be given their vaccine in the vastus lateralis muscle in the thigh if necessary. Utilising the deltoid 
requires stretching of the skin whereas, the vastus lateralis requires pinching of the muscle away from 
the bone during vaccination (see figure 2 and 3) (PHE, 2021a, 2021b). The central and thickest portion 
of the deltoid muscle should be utilised; above the level of the armpit and approximately 2-3 
fingerbreadths below the acromion process. On exposure of the arm, advice should be sought if there 
is bruising, cellulitis or skin irritation at the intended injection site.  
Figure 2 – Deltoid site Both images are from eLFH so will require a stock image or redo.  
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Injection technique  
1. Gather the required equipment; Box 1 outlines required equipment, however, ensure local 
guidelines are followed as equipment will vary depending on the vaccine administered and 
the local procedure for administration (i.e.: drawing up and dosing / dosing only).  







2. Ensure privacy and dignity, decontaminate hands, and apply PPE as per local policy  
3. Apron and gloves are not usually required for vaccine dosing but adherence to PPE 
requirements for C-19 measures must be followed  
4. The injection site does not need to be cleaned unless visibly dirty. If cleaning is required, water 
should be used, and the area dried with a gauze swab. It is not necessary to disinfect the skin.  
5. Stretch the skin at the site of injection - this displaces the subcutaneous tissue and aids needle 
entry (Grafton et al, 2020). This is a straight IM injection technique and Z-track should not be 
used (Brown and Nickalls, 2021)  
6. Using a swift, dart like motion, insert the needle at a 90-degree angle, far enough to ensure 
the vaccine is delivered into the muscle. The is no requirement to leave a length of needle 
exposed, this has been demonstrated as ritualistic practice (Greenway, 2014). Clinical 
judgement should be utilised to ensure the needle is located within the muscle – this is a 
Cleaned receptacle 
Gauze swab / cotton wool 
Vaccine vial  
Alcohol wipe (for vial stopper if drawing up) 
Appropriately sized syringe (1ml) 
Appropriately sized needle 
Sharps box – placed in close proximity to the 
vaccinator (Health and Safety Executive, 2013) 




- 9 - 
 
single-handed technique. Do not rest the thumb on the plunger whilst inserting. See figure 
4. Figure 4 is from eLFH training, will require a redo or permission to use 
7. Aspiration of the plunger is not required due to the absence of large blood vessels at 
designated injection sites for C-19 vaccination. Aspiration is only required when the 
dorsogluteal site is used, which is no longer recommended for IM injection due to proximity 
to large blood vessels and the sciatic nerve (Greenway, 2014; Shepherd, 2018; Ogston-Tuck, 
2014).  
8. Depress the plunger - Ensure the full dose is administered as a partial dose will not evoke a 
full immune response 
9. Gently remove the needle 
10. Apply light pressure with gauze / cotton wool if bleeding occurs – do not rub. If the individual 
has a bleeding disorder, apply firm pressure to the site for at least 2 minutes without rubbing.  
11. Discard used needle and syringe immediately in to sharps container, which should be in close 
proximity to the vaccination site 
12. Discard all used equipment appropriately and decontaminate as per local procedure 
(Adapted from Brown and Nickalls, 2021; Grafton et al, 2020; Greenway, 2014; Ogston-Tuck, 2014; 
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Figure 4 – IM injection technique for C-19 vaccination 
 
Post vaccination observation and documentation 
The vaccinee should be provided with printed information in an accessible format following 
vaccination, alongside a date for further vaccination (for first dosing).  
The vaccinee should be observed for 15 minutes (30 minutes for an individual with previous urticarial 
reaction).  
Documentation of vaccination should include:  
• Vaccine name 
• Product name 
• Batch number 
• Expiry date 
• Dose administered 
• Date vaccination given 
• Route/site used 
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• Name and signature of vaccinator (PHE, 2021a, 2021b) 
Following dosing any suspected side effects should be reported via the yellow card scheme 
https://coronavirus-yellowcard.mhra.gov.uk/.  Overall reporting is approximately 3-4 yellow cards per 
1,000 doses given, the majority relating to injection site reactions and ‘flu-like’ symptoms, an expected 
immune response. Severe allergies are very rare, of the order of 1-2 per 100,000 doses (MHRA, 2021).  
Overall, given the millions of exposures to C-19 vaccines, it is clear that approved vaccines are safe 
and well tolerated.  
Conclusion 
Effective, evidence-based injection technique of C-19 vaccines will ensure a maximal immune 
response for the individual, which will confer benefits to the wider population as the rate of 
vaccination increases. The reader should continue to refer to national guidelines and publications 
which are subject to frequent updates based on latest data, research findings and the emergence of 
new vaccines. The ‘Green Book – chapter 14a’ and the ‘COVID-19 programme guidance for healthcare 
workers‘ contains up to date guidance on C-19 vaccines, the dose and schedule for the UK and 
recommendations for use of the vaccine (PHE, 2021a, 2021b). 
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